Editor's Letter

Published on 29 December 2022

The importance of trust

It seems as if the entire world is dealing with a lack of trust, even in many things that have enriched and sustained human development, including our neighbours, teachers, the press, corporations, politicians, religious leaders, scientists, academic institutions, governments, and even the basic concepts of democracy. Lack of trust is posing a direct threat to…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2022.1103.014

Author(s): Jennifer Campbell

Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Cytarabine Accord 100 mg/mL in punctured original vials and after dilution with 0.9% sodium chloride solution in polyolefine (PO) bags stored at room temperature. Methods: Cytarabine Accord 100 mg/mL was diluted with…

concentrated solution, cytarabine, diluted infusion solution, physicochemical stability

DOI: 10.5639/gabij.2024.1302.024

Editor's Letter

Published on 03 May 2023

Lagging acceptance of generic and biosimilar drug products; the rest of the story

The article in this issue of the GaBI Journal reminded me of The Rest of the Story radio programme originally hosted by Mr Paul Harvey that started each episode with, ‘And now for the rest of the story’. This is because these articles illustrate that sometimes what is not discussed in an article can be…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2023.1201.001

Author byline as per print journal: Irene Krämer, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Methotrexate Accord 25 mg/mL concentrate in punctured original vials and after dilution with 0.9% sodium chloride or 5% glucose solution in 100 mL non-PVC bags containing 0.1 mg/mL and 20 mg/mL methotrexate stored at different…

concentrated solution, diluted infusion solution, methotrexate, physicochemical stability

DOI: 10.5639/gabij.2024.1302.029

Editor's Letter

Published on 14 September 2023

Extrapolation requires reading between the lines

The articles in this second issue of 2023 include an Original Research (Internet questionnaire) of the ‘opinions’ of Canadian ophthalmologists, a Review Article describing a statistical method to assess the ‘drift’ in the attributes of a reference, originator biological product, a Perspective (opinion) article questioning the value of ethnic sensitivity studies (ESS) in the evaluation of…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2023.1202.007

Author(s): Christopher Gillespie, Jennifer Campbell, Michael Phillips

Editor's Letter

Published on 08 September 2022

What to look forward to in GaBI Journal, 2022, Issue 2

The rate of successful development, regulatory approval and marketing of both new and follow-on biological treatments has continued to accelerate despite, and in some cases because of, a seemingly endless list of disturbing world events. This GaBI issue contains manuscripts discussing a variety of topics that are already or promise to be critical to maintaining…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2022.1102.008

Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Etoposide Accord concentrate in punctured vials and after dilution to the concentrations 0.2 mg/mL, 0.4 mg/mL and 0.45 mg/mL in commonly used infusion fluids and containers. Methods: Test solutions were prepared aseptically…

concentrated solution, diluted infusion solution, etoposide, HPLC, physicochemical stability

DOI: 10.5639/gabij.2024.1302.018

Author(s): Michael Cohan

Innovator drug sourcing challenges

Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Docetaxel Accord infusion solutions 0.3 mg/mL and 0.9 mg/mL in non-PVC-bags either pre-filled with 0.9% sodium chloride solution or 5% glucose solution for up to 98 days. Methods: Docetaxel Accord 20 mg/mL…

diluted infusion solution, docetaxel, HPLC, physicochemical stability

DOI: 10.5639/gabij.2024.1302.028

Abstract: CinnaGen, the largest biopharmaceutical company in the MENA region, is a leader in developing follow-on biologicals/biosimilars. Dr Haleh Hamedifar, Chairperson of CinnaGen, spoke to GaBI (Generics and Biosimilars Initiative) about the company’s strategic focus, which includes expanding its product portfolio, entering highly regulated global markets, and advancing affordable treatments for conditions such as multiple…

Author(s): GaBI Journal Editor

biosimilars, clinical development, commercialization, MENA (Middle East and North Africa)

DOI: 10.5639/gabij.2024.1303.037